Savara (SVRA) Stock Price & Analysis

SVRA$4.64-0.08 -1.69%
BiotechnologyGrowth Stock
Compare
Market cap$1.02BEnterprise value$980.68MRevenue (TTM)$0Market position—

Score

67
Bullish
Value
54
Quality
47
Growth
100

AI Analysis

Snapshot

Savara is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 67/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~116% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

54
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

47
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Savara Inc. (SVRA) last printed $4.64. Equity value is $1.02B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$400,000.00$0.00$0.00$0.00$257,000.00$0.00$0.00$0.00$0.00$0.00

About

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Savara (SVRA) Stock Price & Analysis

SVRA price $4.64 -0.08 -1.69%

Ticker
SVRA
Price
$4.64
Change
-0.08 -1.69%
Market cap
$1.02B
Forward P/E
160.67
Dividend yield
0.00%
Beta
0.25
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
67
Value
54
Quality
47
Growth
100

Stocklytics score rationale: value 54, quality 47, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener